SKU Growth Is a Sign of Innovation and Complexity
In medical device manufacturing, SKU proliferation is rarely a mistake. It reflects innovation, product variation, regulatory differentiation, packaging changes, and customer-specific requirements. As portfolios expand across consumables, devices, and regional variants, SKU counts increase naturally.
From a commercial perspective, growth in product breadth is often positive. It allows organizations to serve more customers, compete more precisely, and address specialized needs. The risk is not growth itself. The risk is losing pricing accountability as that growth compounds.
When SKU counts expand faster than pricing governance evolves, oversight begins to thin.
Aggregate Margin Masks SKU-Level Drift
As portfolios grow, pricing performance is increasingly evaluated at an aggregate level. Gross margin by product line or business unit may appear stable. Revenue growth may remain on track. On the surface, nothing seems broken.
The challenge emerges at the SKU level.
Individual products may be misaligned with current pricing rules. Legacy SKUs may persist with outdated pricing logic. Manual overrides introduced years earlier may remain embedded in the system. New SKUs may be priced inconsistently relative to comparable products.
When performance is reviewed in aggregate, these issues are difficult to detect. Strong SKUs quietly offset weak ones. Margin variability is absorbed across the portfolio.
What appears to be stable margin control may actually be cross-subsidization.
SKU Complexity Dilutes Pricing Accountability
In high-SKU medical device environments, pricing ownership can become diffuse. Who is responsible for ensuring that every SKU reflects current pricing discipline? Commercial operations may manage price lists. Product management may influence positioning. Sales may request adjustments. Finance may review results.
Without clear structure, accountability weakens.
Over time, pricing logic becomes uneven across the catalog. Some SKUs reflect governed, updated pricing frameworks. Others persist through inertia, untouched because they do not trigger immediate concern. As new products are introduced, pricing decisions may rely more on precedent than on structured analysis.
This creates a layered portfolio where pricing discipline is inconsistent, even if unintentional.
SKU-Level Pricing Risk Is Hard to See but Easy to Accumulate
The most dangerous pricing risks are often not dramatic. They accumulate quietly.
A small margin gap on a high-volume consumable.
A discounted SKU that was never recalibrated.
A regional variant priced inconsistently with its global counterpart.
Individually, these discrepancies may appear immaterial. Across hundreds or thousands of SKUs, they compound.
In medical device manufacturing, recurring orders magnify these effects. A minor pricing misalignment repeated at scale becomes structural margin erosion. And because it hides inside aggregate reporting, leadership may not recognize it until financial pressure intensifies.
Why SKU-Level Pricing Accountability Matters
Lack of SKU-level accountability introduces hidden margin risk. It reduces confidence that pricing outcomes reflect intentional discipline rather than historical accumulation. As scrutiny increases, executives may struggle to explain why similar products carry materially different pricing logic or margin profiles.
Restoring SKU-level visibility is not about micromanaging individual products. It is about ensuring that pricing structure scales with portfolio complexity. When every SKU can be traced back to consistent logic and governance, leadership gains confidence that margin performance reflects controlled decisions.
In complex medical device portfolios, margin control depends on SKU-level clarity. Without it, pricing drift becomes structural before it becomes visible.
Unsure whether every SKU reflects disciplined pricing logic? Contact us to learn how Zilliant Pricing Plus helps medical device manufacturers restore SKU-level pricing accountability and margin control: zilliant.com/contact-us
